In 2007 the Sales of Insulin and Analogue in China

[admin]

DUBLIN, Ireland, Oct 10, 2008 (BUSINESS WIRE) -- Research and Markets ( http://www.researchandmarkets.com/resea ... esearch_of) has announced the addition of the "Market Research of Diabetes and its Treatment Medicine-Insulin in China, 2008" report to their offering.
According to IMS statistics, in 2007 the scale of global anti-diabetes drug market was $24.1 billion, up 13.7 per cent year-on-year, ranking No.5 of the global pharmaceutical market and is expected to have 15 to 20 per cent growth in the future.
According to the International Diabetes Federation (IDF) report that China had 39.8 million people have diabetes in 2007, ranking No.2 in the world, with a total morbidity of 3.1 per cent and is expected in 2025 will reach 59.3 million, 2.6 times than 1990, the annual growth rate is 10%, the average annual net increase of 1.5 million.
In terms of the current trend of diabetes in the developing countries, that the prediction of IDF is relatively conservative, the fact is the growth of diabetics is expected to be further great in the future in China; the reasons are, firstly, China has a large population and the growth is relatively fast; Secondly, the aging of the population has grown greatly; thirdly, the speed up of urbanization process which affected people's lifestyle, less physical activity and eat more junk food lead to people's overweight and obesity.
From 2002 to 2006, China's diabetes drug market had been steady growth; its average annual growth rate was 12% and in 2007 reached 7.495 billion yuan, an increase of 20.98 per cent than 2006, which was 6.195 billion yuan.
The growth of Insulin's sales and its similar drugs is the main driving force for the expansion of China's diabetes drug market. In 2007 the sales of insulin and analogue reached 1.919 billion yuan, up 55.81 per cent year-on-year, accounting for 33.61 per cent of China's diabetes drug market, increased 2.24 per cent than 2006. Although the market share of insulin and its analogues have increased gradually, but still less than the average level of global market which is 40.1 per cent, therefore, there is still plenty room for the development of China's Insulin market.
Tonghua Dongbao is a leading medicine company in China; its insulin is the only domestic insulin on the directory of China national health insurance B drug. In terms of the national health insurance system, A drug is able to 100 per cent apply for reimbursement and B drug is apply for reimbursement in proportion. Generally, foreign and domestic insulin is hardly to enter the list of A drug; this is a advantage of Tonghua Dongbao's insulin in terms of its low price, insulin is a lifelong drug and price is considered more sensible by most patients, as in the similar consequence of various drugs, perhaps patients are more like to choose Tonghua Dongbao's insulin which is 30 per cent cheaper than foreign insulin.
From 2008, the central government and local governments will invest more to improve the national health insurance system. 60 per cent market of Tonghua Dongbao's insulin is in second-line cities, where piece is the most sensitive factor for patients; therefore, Tonghua Dongbao's insulin will be their first choice.
Key Topics Covered:
1 The current circumstance of diabetes and its development trend
1.1 Brief of diabetes
1.1.1 The definition of diabetes
1.1.2 Classification of diabetes
1.1.3 The cause of diabetes
1.1.4 Diagnostic criteria of diabetes
1.1.5 The natural course of diabetes
1.1.6 The application of diabetes treatment drug
1.2 The rapid growth of the global diabetics
1.3 The numbers of diabetics in China
1.4 The Growth number of the Chinese diabetics is higher than expected
1.4.1 The huge population leads to the large number of diabetics
1.4.2 The rapid growth of aging population is a main factor
1.4.3 The Urbanization and lifestyle changes indirectly lead to high opportunity for diabetes
2 The development of Insulin industry
2.1 Brief of Insulin
2.2 The rapid expansion of the global insulin drug market
2.3 The growth of China insulin drug market
2.4 Comparison of the insulin market competition between China and global
2.4.1 Insulin is a high-investment and high-return industry
2.4.2 The less competition in the internal insulin industry
2.4.3 The less pressure from the new comers
2.4.4 The pressure from insulin substitute manufacturers
2.4.5 Suppliers of insulin
2.4.6 Buyer of insulin
2.5 Insulin market will continue to expand
2.5.1 Expansion will be benefited from the rising average income
2.5.2 Expansion will be benefited from the reform of Chinese national health system
2.6 Differentiation of the global consumption of insulin
3 Analysis of Tonghua Dongbao
3.1 Brief
3.2 Performance
3.3 Competition
Figures
The clinical application of the various diabetes drugs
The global growth number of diabetics 1985-2025
Distribution of global diabetics
Prediction of the number of diabetics in developed countries 2025
Prediction of the number of diabetics in developing countries
The growth number diabetics in China 1978-2025
The age structure of China population
The morbidity of diabetes by age
The IGT and DM of diabetes by age
The trend of aging in China since 2000
China's urbanization rate of the population 1995-2020
The primary structure of insulin
The global diabetes drug market 2004-2007
The Chinese market share and growth of diabetes drugs in hospital and pharmacy
Comparison of the research investment of Novo Nordisk, Eli Lilly and Sanofi- Aventis since 2001
The market share of the three international insulin giants
Comparison of the numbers of diabetic and expenditure 2007
The average income of urban residents and health care spending
The average income of rural residents and health care spending
The sales growth of Novo Nordisk's insulin in the Chinese market
The market share and growth of Eli Lilly's second-generation insulin
The increase of Tonghua Dongbao's gross profit ratio
The 2008 mid-term financial statement of Tonghua Dongbao
Tables
Classification of diabetes
The clinical stage of diabetes of classification and diagnosis
Forecast of the numbers of diabetics with insulin-dependent
The forecast of the numbers and morbidity of diabetes and IGT of the world
The world's top 10 countries of diabetic
The DM and IGT morbidity of the different BMI people
The world's top 10 diabetes drugs 2007
The growth of insulin and its analogue market 2006-2007
The top 10 diabetes drug treatment hospitals and their growth ratio 2005-2007
The sales of various products of insulin of three companies 2004-2007
The insulin market share of the top five products 2005-2007
The price of retail and bid inviting of insulin in China
Companies Mentioned:
- Tonghua Dongbao
- Novo Nordisk
- Eli Lilly
For more information visit http://www.researchandmarkets.com/resea ... esearch_of
SOURCE: Research and Markets

Research and Markets
Laura Wood, Senior Manager
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
press@researchandmarkets.com